Gedatolisib

Unknown Manufacturer

Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.

Generate AI report

Overview

Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.

Technical identifiers

Chemical Formula: C₃₂H₄₁N₉O₄
CAS Number: 1197160-78-3
UNII ID: 96265TNH2R

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA (GEDATOLISIB) AND ITS COMBINATIONS FOR USE IN THE TREATMENT OF BREAST CANCER
EP 4376848 B1Applicant: CELCUITY INCPriority: 2021
EP
US
WO
6 publications
TREATMENT OF OCULAR DISEASES USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL)PHENYL)-3-[4-(4,6- DIMORPHOLIN-4- YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA
WO 2025128712 A1Applicant: CELCUITY INCPriority: 2023
CN
WO
2 publications
TREATMENT REGIMENS FOR GEDATOLISIB IN HORMONALLY-DRIVEN DISORDERS
US 20260053814 A1Applicant: CELCUITY INCPriority: 2024
US
WO
2 publications
Preparation method of Gedatolisib and intermediate
CN 108456183 AApplicant: UNIV SHANGHAI ENG SCIENCEPriority: 2018
CN
药物组合及其应用
CN 115671289 BApplicant: 广州嘉越医药科技有限公司Priority: 2021
CN
COMBINATION CANCER TREATMENTS WITH A COMPOSITION COMPRISING AN MTOR PATHWAY INHIBITOR
WO 2025049962 A1Applicant: AADI BIOSCIENCE INCPriority: 2023
WO
Preparation method of Gedatolisib key intermediate
CN 118745159 AApplicant: ZHEJIANG UNIV QUZHOU RESEARCH INSTITUTEPriority: 2024
CN
Application of small molecule compound in preparation of product for inhibiting 3C-like cysteine protease
CN 120570893 AApplicant: INST MILITARY MEDICINE ACADEMY MILITARY SCIENCES PLAPriority: 2025
CN

Drugs